Two Sigma Investments LP Cuts Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Two Sigma Investments LP reduced its position in Cellebrite DI Ltd. (NASDAQ:CLBTFree Report) by 14.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,349,659 shares of the company’s stock after selling 227,733 shares during the period. Two Sigma Investments LP owned about 0.66% of Cellebrite DI worth $29,733,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. State of Wyoming increased its stake in shares of Cellebrite DI by 44.6% during the 4th quarter. State of Wyoming now owns 30,911 shares of the company’s stock worth $681,000 after purchasing an additional 9,530 shares in the last quarter. Silvercrest Asset Management Group LLC acquired a new stake in Cellebrite DI during the 4th quarter valued at $4,583,000. Polar Capital Holdings Plc increased its position in Cellebrite DI by 61.8% during the fourth quarter. Polar Capital Holdings Plc now owns 448,801 shares of the company’s stock worth $9,887,000 after buying an additional 171,404 shares in the last quarter. Man Group plc acquired a new position in shares of Cellebrite DI in the fourth quarter worth $2,385,000. Finally, Nuveen Asset Management LLC raised its holdings in shares of Cellebrite DI by 38.5% in the fourth quarter. Nuveen Asset Management LLC now owns 585,839 shares of the company’s stock worth $12,906,000 after acquiring an additional 162,886 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CLBT. Lake Street Capital increased their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, May 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $22.43.

Check Out Our Latest Analysis on Cellebrite DI

Cellebrite DI Trading Up 0.2%

NASDAQ CLBT opened at $17.05 on Wednesday. The business’s 50-day moving average price is $19.01 and its 200 day moving average price is $20.23. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The company has a market capitalization of $4.08 billion, a PE ratio of -12.27, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The company had revenue of $107.55 million during the quarter, compared to the consensus estimate of $109.36 million. During the same quarter in the prior year, the company posted $0.08 EPS. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. Equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

About Cellebrite DI

(Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Featured Articles

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.